The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin
(Mylotarg), ibritumomab riuxetan (Zevalin), panitumumab (Vectibix), tositu-momab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
MYLOTARG(R) (gemtuzumab ozogamicin
) is contraindicated in patients with a known hypersensitivity to gemtuzumab ozogamicin
or any of its components and in lactating mothers.
Effi cacy and safety of gemtuzumab ozogamicin
in patients with CD33-positive acute myeloid leukemia in first relapse.
Tokyo, Japan, July 27, 2005 - (JCNN) - Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin
, from the Ministry of Health, Labor and Welfare.
Investigator Research on Several Pfizer Compounds to be Presented Including an ASH Plenary Presentation on Gemtuzumab Ozogamicin
He was also a key contributor to the discovery and development of gemtuzumab ozogamicin
, known commercially as Mylotarg, the first monoclonal antibody approved by the Food and Drug Administration to treat acute myeloid leukemia.
A second phase II study from the MD Anderson Cancer Center concluded that the effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin
(FLAG-GO) is a highly effective regimen and has resulted in high rate of relapse-free survival in patients with newly diagnosed patients with core-binding factor AML.
1304) Gemtuzumab Ozogamicin
(Mylotarg(R)) as a Single Agent To Evaluate Safety and Determine Maximum Tolerated Dose (MTD) in Post Hematopoietic Stem Cell Transplant Patients with Relapsed, CD33+Acute Myeloid Leukemia (AML).
In this role, she led late-stage clinical development for bosutinib and gemtuzumab ozogamicin
Azacitidine Plus Gemtuzumab Ozogamicin
(GO): A Novel Combination in the Treatment of AML and High-Risk MDS in the Elderly Abstract ID: 1981 Sucha Nand, et al.
Patients given the new type of "smart drug" called Gemtuzumab Ozogamicin
(GO) as well as chemotherapy were 22% less likely to relapse and around 13% less likely to die from their disease.
The research team studied more than 1,000 patients who received a combination of chemotherapy and the drug Gemtuzumab Ozogamicin
, which is also known as Mylotarg.